Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
Celyad Oncology SEJanuary 11, 2021 GMT
MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors.
“I am very pleased to welcome Marina to our Board of Directors,” stated Filippo Petti, CEO of Celyad Oncology. “As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from Marina’s wealth of experience as we continue to advance key elements of our pipeline with the goal of developing innovative cell therapies against cancer.”
Celyad Oncology SA: Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
Regulatory News:
Celyad Oncology SA (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors. I am very pleased to welcome Marina to our Board of Directors, stated Filippo Petti, CEO of Celyad Oncology. As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from Marina s wealth of experience as we continue to advance key elements of our pipeline with the goal of developing innovative cell therapies against cancer.
Leslie Iltgen appointed Head of Investor Relations & Corporate Communications at Jenoptik optics.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from optics.org Daily Mail and Mail on Sunday newspapers.
(2)
Regulatory News:
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD) (the Company ), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it has entered into a committed equity purchase agreement ( Purchase Agreement ) for up to $40 million with Lincoln Park Capital Fund, LLC ( LPC ), a Chicago-based institutional investor.
Over the 24-month term of the Purchase Agreement, the Company will have the right to direct LPC to purchase up to an aggregate amount of $40 million American Depositary Shares ( ADSs ), each of which represents one ordinary share of the Company. LPC s maximum obligation under any single regular purchase will not exceed $2.5 million, unless both parties mutually agree to increase the maximum amount of such purchase. The purchase price for the ADSs to be purchased by LPC under a regular purchase will be the equal to
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital
Celyad Oncology SEJanuary 7, 2021 GMT
MONT-SAINT-GUIBERT, Belgium, Jan. 07, 2021 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it has entered into a committed equity purchase agreement (“Purchase Agreement”) for up to $40 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.
Over the 24-month term of the Purchase Agreement, the Company will have the right to direct LPC to purchase up to an aggregate amount of $40 million American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company. LPC’s maximum obligati